Company LAVA Therapeutics N.V.

Equities

LVTX

NL0015000AG6

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-23 pm EDT			5-day change	1st Jan Change
2.98 ^USD	+4.56%		+3.11%	+88.61%

Mar. 20	LAVA Therapeutics N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 20	LAVA Therapeutics N.V. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

LAVA Therapeutics NV, formerly known as Lava Therapeutics BV, is a provider of biotechnology research and development services based in the Netherlands. The Company focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.

Number of employees: 37

USD in Million	2022	Weight	2023	Weight	Delta
Novel Bispecific Antibodies 100.0 %	20	100.0 %	7	100.0 %	-64.09%

USD in Million	2022	Weight	2023	Weight	Delta
Netherlands 100.0 %	20	100.0 %	7	100.0 %	-64.09%

Managers	Title	Age	Since
Stephen Allen Hurly CEO	Chief Executive Officer	56	19-05-31
Fred M. Powell DFI	Director of Finance/CFO	63	22-10-31
Jessica Truscello CTO	Chief Tech/Sci/R&D Officer	-	21-11-08
Hans van der Vliet CTO	Chief Tech/Sci/R&D Officer	50	16-12-31
Charles Q. Morris CTO	Chief Tech/Sci/R&D Officer	59	23-02-05
Paul W. H. I. Parren CTO	Chief Tech/Sci/R&D Officer	60	18-04-30
Robin Hume LAW	General Counsel	-	23-05-14
Wouter van Hunnik HRO	Human Resources Officer	-	21-11-08
Amy Garabedian LAW	General Counsel	-	21-07-26
Peter Ros PRN	Corporate Officer/Principal	52	19-12-31

Members of the board	Title	Age	Since
Stephen Allen Hurly CEO	Chief Executive Officer	56	19-05-31
Karen Wilson BRD	Director/Board Member	61	21-03-31
James Noble BRD	Director/Board Member	65	22-06-14
Peter Kiener BRD	Director/Board Member	72	22-12-31
Jay Backstrom BRD	Director/Board Member	69	22-06-14
Kapil Dhingra CHM	Chairman	64	21-02-21
Mary Wadlinger BRD	Director/Board Member	64	22-12-31
Christy Oliger BRD	Director/Board Member	54	23-03-08

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	26,289,087	18,738,315 ( 71.28 %)	0	71.28 %

Name	Equities	%	Valuation
Gilde Healthcare Partners BV 20.62 %	5,421,170	20.62 %	18 M $
Versant Venture Management LLC 17.45 %	4,587,837	17.45 %	15 M $
Redmile Group LLC 7.891 %	2,074,372	7.891 %	7 M $
SANOFI 7.301 %	1,919,455	7.301 %	6 M $
Tang Capital Management LLC 3.197 %	840,593	3.197 %	3 M $
Bruce & Co., Inc. 2.936 %	771,874	2.936 %	3 M $
Alpha Wave Global LP 0.4105 %	107,906	0.4105 %	359 327 $
Hans van der Vliet 0.2942 %	77,350	0.2942 %	257 576 $
Amy Garabedian 0.2568 %	67,499	0.2568 %	224 772 $
PNC Financial Services Group, Inc. (13F Subfiler) 0.2473 %	65,000	0.2473 %	216 450 $

LAVA Therapeutics NV

Yalelaan 62

3584 CM, Utrecht

+31 85 016 3100

http://www.lavatherapeutics.com

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.785 EUR

Average target price

6.684 EUR

Spread / Average Target

+139.98%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
LAVA THERAPEUTICS N.V.	+88.61%	78.34M
IQVIA HOLDINGS INC.	+3.13%	43.43B
LONZA GROUP AG	+47.64%	41.69B
MODERNA, INC.	+8.49%	41.31B
CELLTRION, INC.	-10.82%	27.14B
ICON PUBLIC LIMITED COMPANY	+8.26%	25.28B
ALNYLAM PHARMACEUTICALS, INC.	-23.69%	18.47B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.58%	12.33B
MEDPACE HOLDINGS, INC.	+32.83%	12.59B
UNITED THERAPEUTICS CORPORATION	+6.63%	11.03B

Other Biotechnology & Medical Research